SRC
Proto-oncogene tyrosine-protein kinase Src
As of the edition of 20 October 2026, SRC (proto-oncogene tyrosine-protein kinase Src, UniProt P12931) has 10 drugs tested at it and 14 companies on the list, 4 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P12931
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 78
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Lungs and airways; Digestive system; Urinary and reproductive; Hormones
- Registered trials of its drugs
- 478
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Went quiet | 3 |
| Stopped | 4 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Dasatinib anhydrous | Marketed | Phase 4 | Ended 2026 |
| Vandetanib | Marketed | Phase 3 | none listed |
| Saracatinib | Went quiet | Phase 2 | none listed |
| Tirbanibulin | Marketed | Phase 4 | Ends 2038 |
| ENMD-981693 | Went quiet | Phase 2 | none listed |
| Ilorasertib | Stopped | Phase 2 | none listed |
| TG100-801 | Stopped | Phase 2 | none listed |
| XL-228 | Stopped | Phase 1 | none listed |
| AZD-0424 | Stopped | Phase 1 | none listed |
| JNJ-26483327 | Went quiet | Phase 1 | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Route B | 3 |
| Engaged | 5 |
| Undetermined | 2 |
| Total on the list | 14 |
| Company | Route |
|---|---|
| Almirall | Route B |
| Esteve Pharmaceuticals | Route B |
| Johnson & Johnson | Route A |
The other 11 companies at SRC
In the product14 companies in all; 11 are not named here, and no score is.
See the 14 companies at SRC, ranked, with the facts behind eachRequest access. Nothing is shown until you do.